Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Johnson and Johnson
Medtronic
Colorcon

Last Updated: May 19, 2022

ESKATA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Eskata, and what generic alternatives are available?

Eskata is a drug marketed by Aclaris and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-one patent family members in eighteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.

DrugPatentWatch® Generic Entry Outlook for Eskata

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2022. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for ESKATA
International Patents:31
US Patents:6
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 145
Patent Applications: 4,138
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ESKATA?ESKATA excipients list
DailyMed Link:ESKATA at DailyMed
Drug patent expirations by year for ESKATA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ESKATA
Generic Entry Date for ESKATA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ESKATA

ESKATA is protected by six US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ESKATA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ESKATA

Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Seborrheic keratosis treatment
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

Peroxide formulations and methods and applicators for using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ESKATA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2523731 LUC00159 Luxembourg See Plans and Pricing PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113
2523731 CA 2020 00025 Denmark See Plans and Pricing PRODUCT NAME: OSILODROSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER OSILODROSTATDIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200113
2523731 2020012 Norway See Plans and Pricing PRODUCT NAME: OSILODROSTAT ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV, INKLUDERT OSILODROSTAT DIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Express Scripts
Medtronic
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.